🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. Wumeiwan Jiawei Fang

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Dry Eye Syndromes

    phase 3 small molecule active

    1 trial

  2. XEOMIN 200 V pulveris injekciju šķīduma pagatavošanai, Placebo to NT201, XEOMIN, 200 jednostek, proszek do sporządzania roztworu do wstrzykiwań

    Merz Pharmaceuticals GmbH

    Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)

    phase 3 small molecule active

    1 trial

  3. XEOMIN 200 jednotek prášek pro injekční roztok, XEOMIN, 200 jednostek, proszek do sporządzania roztworu do wstrzykiwań, XEOMEEN 200 eenheden poeder voor oplossing voor injectie, XEOMIN 200 egység por oldatos injekcióhoz, XEOMIN 200 jednotiek prášok na injekčný roztok, XEOMIN 200 unidades polvo para solución inyectable, XEOMEEN 200 unités poudre pour solution injectable, XEOMIN 200 Einheiten Pulver zur Herstellung einer Injektionslösung, XEOMIN 200 unités, poudre pour solution injectable, XEOMIN, 200 unità,

    Merz Pharmaceuticals GmbH

    Lower limb spasticity

    phase 3 small molecule active

    1 trial

  4. Xanomeline and Trospium Chloride Capsules

    Bristol-Myers Squibb Australia Pty Ltd

    Schizophrenia

    phase 3 small molecule completed

    1 trial

  5. Xiang-Sha-Liu-Jun-Zi-Tang

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Irritable Bowel Syndrome

    phase 3 small molecule active

    1 trial

  6. Xofigo 1100 kBq/mL solution for injection

    Ningbo Cancer Hospital

    metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  7. Xtandi - 40 mg soft capsules, Flutamide 250 mg Tablets, Casodex® 50 mg Film-coated Tablets

    Ningbo Cancer Hospital

    Metastatic Prostate Cancer

    phase 3 small molecule active

    1 trial

  8. Xtandi - 40 mg soft capsules, Xofigo 1100 kBq/mL solution for injection

    Ningbo Cancer Hospital

    Castration resistant prostate cancer patients metastatic to bone.

    phase 3 small molecule active

    1 trial

  9. YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion, Revlimid 20 mg hard capsules, Bendamustine 100mg Powder for Concentrate for Solution for Infusion, Vincristine Sulfate 1 mg/ml Solution for Injection or Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Endoxana Injection 1000 mg Powder for Solution for Injection, Prednisolone 5 mg Soluble Tablets, MabThera 500 mg concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  10. YiQiFang

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cancer

    phase 3 small molecule completed

    2 trials

  11. Yinhu Qingwen Granula

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 3 small molecule on hold

    1 trial

  12. Ypeginterferon alfa-2b

    The First People's Hospital of Lianyungang

    Chronic Hepatitis B

    phase 3 small molecule completed

    3 trials

  13. ZX008 (Fenfluramine Hydrochloride)

    International Peace Maternity and Child Health Hospital

    Dravet Syndrome

    phase 3 small molecule completed

    1 trial

  14. Zelenectide Pevedotin, BT8009, PEMBROLIZUMAB, AVELUMAB, CISPLATIN, CARBOPLATIN, GEMCITABINE

    BICYCLE THERAPEUTICS

    Locally advanced or metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  15. Zimberelimab, CARBOPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOMVANALIMAB, CISPLATIN , PACLITAXEL , Abraxane 5 mg/ml powder for dispersion for infusion., ALIMTA 500 mg powder for concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Metastatic Non–Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  16. Zipalertinib Placebo Tablets is a film-coated tablet that does not contain the active ingredient, zipalertinib., Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Zipalertinib, Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Taiho Pharma Netherlands B.V.

    Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations

    phase 3 small molecule active

    1 trial

  17. Zoladex 3,6 mg implante en jeringa precargada, Decapeptyl semestral 22,5 mg polvo y disolvente para suspensión de liberación prolongada inyectable., Eligard semestral 45 mg polvo y disolvente para solución inyectable., Bicalutamida Aristo 50 mg comprimidos recubiertos con película EFG

    The George Institute

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  18. Zolgensma 2 × 10^13 vector genomes/mL solution for infusion

    Novartis Pharmaceuticals

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  19. Zometa 4 mg/100 ml solution for infusion

    Ningbo Cancer Hospital

    High grade osteosarcoma

    phase 3 small molecule active

    1 trial

  20. a compound glutamine capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mucositis

    phase 3 small molecule active

    1 trial

  21. a compound glutamine capsule/a compound glutamine capsule simulated placebo

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mucositis

    phase 3 small molecule active

    1 trial

  22. a patient self-reporting applet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cancer Pain

    phase 3 other active

    1 trial

  23. administering RASI (the trade name or universal name will not be stipulated) before stenting

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Carotid Stenosis

    phase 3 small molecule active

    1 trial

  24. adoptive immunotherapy

    Chinese PLA General Hospital

    Hepatocellular Carcinoma

    phase 3 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources